Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: axcellahealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2021 | $10.00 → $12.00 | Buy | Chardan Capital |
| 10/12/2021 | $6.00 | Outperform | Noble Capital Markets |
| 9/22/2021 | $9.00 → $5.00 | Buy → Neutral | Goldman Sachs |
| 7/30/2021 | Neutral → Underweight | JP Morgan | |
| 7/6/2021 | $14.00 | Buy | HC Wainwright & Co. |
4 - Axcella Health Inc. (0001633070) (Issuer)
4 - Axcella Health Inc. (0001633070) (Issuer)
4 - Axcella Health Inc. (0001633070) (Issuer)
4 - Axcella Health Inc. (0001633070) (Issuer)
4 - Axcella Health Inc. (0001633070) (Issuer)
4 - Axcella Health Inc. (0001633070) (Issuer)
4 - Axcella Health Inc. (0001633070) (Issuer)
4 - Axcella Health Inc. (0001633070) (Issuer)
3 - Axcella Health Inc. (0001633070) (Issuer)
3 - Axcella Health Inc. (0001633070) (Issuer)